Replies to post #212115 on Biotech Values

[zipjet]

a product won’t be eligible for FDA interchangeable status unless the sponsor has the analytical tools to prove a high degree of sameness to the reference brand.

Sounds like another reason some company should acquire MNTA.

[DewDiligence]

MNTA bold prediction:

https://twitter.com/DewDiligence/status/879807089010515968 (scan up)

[DewDiligence]

(MNTA)—B-I starts switching study for Humira FoB:

http://www.businesswire.com/news/home/20170727005789/en/Boehringer-Ingelheim-starts-clinical-study-interchangeability-adalimumab

The point of a switching study is to seek FDA interchangeable status.